Wells Fargo & Company Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $20.00

Viridian Therapeutics (NASDAQ:VRDN) had its target price cut by Wells Fargo & Company from $29.00 to $20.00 in a research note released on Tuesday,Benzinga reports. They currently have an equal weight rating on the stock.

Other equities analysts have also issued reports about the stock. HC Wainwright lowered their price objective on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday. Royal Bank Of Canada cut their price objective on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, January 21st. William Blair began coverage on shares of Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Finally, Truist Financial dropped their price target on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Viridian Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics Stock Down 1.6%

Viridian Therapeutics stock opened at $18.84 on Tuesday. Viridian Therapeutics has a twelve month low of $9.90 and a twelve month high of $34.29. The stock has a 50 day moving average of $28.63 and a two-hundred day moving average of $27.77. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -5.73 and a beta of 1.16.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $15.75 million. As a group, research analysts expect that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Viridian Therapeutics by 29.6% in the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after buying an additional 1,280,161 shares in the last quarter. Commodore Capital LP grew its stake in Viridian Therapeutics by 35.4% in the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after acquiring an additional 1,275,000 shares during the last quarter. State Street Corp grew its stake in Viridian Therapeutics by 35.7% in the 4th quarter. State Street Corp now owns 3,466,560 shares of the company’s stock valued at $107,879,000 after acquiring an additional 912,394 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Viridian Therapeutics by 42.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock valued at $107,036,000 after acquiring an additional 1,021,310 shares in the last quarter. Finally, Perceptive Advisors LLC raised its position in Viridian Therapeutics by 108.1% during the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock worth $94,689,000 after acquiring an additional 1,580,303 shares during the last quarter.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Topline REVEAL-1 Phase III results reported clinical activity for elegrobart — supports the drug’s efficacy and preserves an approval/commercial pathway, which is a material long-term positive for VRDN. Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
• Positive Sentiment: Some analysts remain constructive on longer-term upside: HC Wainwright maintains a Buy and has modeled recovery into FY2029–2030 (including a FY2030 EPS projection), reflecting belief in commercial potential beyond near-term noise. (Market commentary / analyst note summaries)
• Neutral Sentiment: Short-term trading has been volatile — the stock saw large swings on volume as the market digested nuanced efficacy/market-position takeaways; that raises short-term uncertainty but also increases liquidity for active traders. Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
• Negative Sentiment: Market reaction included a sharp pre-market drop (reported ~41% at one point) as investors judged the results insufficiently dominant versus competitors and priced in execution/market-share risk. VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal?
• Negative Sentiment: Several firms lowered expectations/targets after the readout: Goldman cut its price target, Wells Fargo trimmed its target to $20, and other notes signaled more cautious near-term forecasts — increasing near-term downside risk from analyst-driven flows. The Goldman Sachs Group Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 Wells Fargo & Company Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $20.00 Wedbush Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
• Negative Sentiment: Critical takes emphasize that REVEAL-1 returned clinically meaningful but not clearly market-dominant data, which may limit peak sales vs. competitors and lengthen the commercialization ramp — a negative for near- to medium-term valuation. Viridian’s REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.